A Comprehensive Review on Schisandrin B and Its Biological Properties

Nasser, M. I.; Zhu, Shuoji; Chen, Chen; Zhao, Mingyi; Huang, Huanlei; Zhu, Ping

doi:https://doi.org/10.1155/2020/2172740

Oxidative Medicine and Cellular Longevity

On this page

Abstract Introduction Conclusion Conflicts of Interest Authors’ Contributions Acknowledgments References Copyright Related Articles

Review Article | Open Access

Volume 2020 | Article ID 2172740 | https://doi.org/10.1155/2020/2172740

A Comprehensive Review on Schisandrin B and Its Biological Properties

M. I. Nasser,¹Shuoji Zhu,¹Chen Chen,¹Mingyi Zhao,¹Huanlei Huang,¹and Ping Zhu¹

Academic Editor: Fabiana Morroni

Received15 Jan 2020

Accepted22 Feb 2020

Published16 Mar 2020

Abstract

Nature is a vast source of bioactive molecules and has provided an active and efficient reservoir for drug discovery. Among natural compounds, one of the most promising is Schisandrin B (Sch B), isolated from Schisandra chinensis, which was documented to possess diversified pharmacokinetic propriety, among them antioxidant, anti-inflammation, cardioprotection, and neuroprotection. Due to its large biological properties, Sch B was recorded to be a potent cure for several diseases by targeting several signaling pathways. This review is aimed at emphasizing the recent data on the biological properties of Sch B among the molecular mechanism of this drug on tumoral, cardiac, and neural diseases. The data suggest that the antitumor activities of Sch B were mainly through apoptosis and cell cycle arrest at the diver’s stage. It is reported that Sch B could be used as effective chemotherapy, neuroprotection, and cardioprotection since it possesses a spectrum of biological activities; however, further investigations on the mechanism of its action and preclinical trials are still mandatory to further validate the potential of this natural drug candidate.

1. Introduction

Natural compounds have been broadly used since ancient times to prevent and cure various illnesses in Asian countries mostly. Nature attracts particular attention because it provides a vast source of bioactive molecules. Those molecules have been used separately or as a mixture to cure or prevent cancer, cardiovascular disease, and neurodegenerative disease, among others [1, 2]. Among natural compounds, Traditional Chinese Medicine (TCM) has the characteristics of low toxicity, multiple targets, and integrity, which can be regulated by the machinery of the body immune function, inhibit the formation of tumor tissue neovascularization, promote the death of tumor cells, and reduce the effect of tumor cell resistance to achieve antitumor properties, in the prevention and treatment of cancer prescription surface which have certain advantages [3–5]. Among TCM, Schisandra chinensis has been used for thousands of years to prevent memory deficiency [6]. With the development of technology, Schisandra chinensis is a mixture of several bioactive compounds; among others, we have Sch A, B, and C, which have been used to prevent several illnesses [7, 8]. In the three isoforms of Sch, Sch B attracts particular attention. Previous reports revealed Sch B function in neuroprotection by reducing oxidative stress [9, 10]. In this review, we describe the pivotal role of Sch B in treating cancers, cardiovascular diseases, and neurodegenerative diseases and explain the molecular mechanism as well as the function in several illnesses.

2. Schisandrin B and Antioxidation

Modern pharmacological studies have shown that Sch B could play an essential role in liver protection, antioxidation, antiaging, antitumor, antianxiety, and other aspects. Numerous experiments have shown that Sch B could increase the level of superoxide dismutase (SOD) in cells, inhibit lipid peroxidation, and reduce lactate dehydrogenase and malondialdehyde releasing reactive oxygen species therefore directly removing free radicals and playing an antioxidant role [11, 12]. Indeed, the scavenging effect of hydroxyl free radicals of oxygen free radicals by Sch B was most significant, compared to vitamin C at the same concentration [13]. Lam and Ko [10] found that Sch B has specific antioxidant effects on various tissues, including the brain. Earlier studies have shown that Sch B can increase the activity or content of SOD and glutathione (GSH) in tissue cells and resist free radical pairs of biological damage. Recent studies reported that Sch B could also activate glutathione-s-transferase (GST), glutathione reductase (GRD), and glucose-6-phosphate dehydrogenase (G6PD) activity; improve the level of the GSH antioxidant system; and ultimately protect the oxidative body damage [14, 15]. Sch B can also restore the activity of GSH-PX and other antioxidant enzymes and reduce the production of MDA [16, 17].

Moreover, the antioxidative effect of Sch B was also reported on neuroprotective activities. Sch B was found to regulate the expression of the heat shock protein (HSP) gene in neurons [18]. HSP is a component of the subpartner; HSP70 has been proven to have a neuroprotective effect on antioxidant stress, again demonstrating the clinical prevention and treatment of Sch B broad prospects in treating degenerative diseases of the central nervous system. Besides the above pharmacological effects, Sch B can also prevent oxygen-free radicals from forming biofilm structural and functional damage [19, 20]. Likewise, Sch B was reported to avoid ischemia-reperfusion through exerting antioxidant proprieties [21]. Additionally, it is well known that mitochondria are the production sites of ATP and an essential source of reactive oxygen species dysfunction which can produce excessive reactive oxygen species and cause oxidative stress damage, leading to opening of permeability conversion (MPT) holes, and subsequently result in the breakdown of the organelle membrane potential, a process that could trigger ATP synthase to work in reverse, further accelerating ATP depletion, ion homeostasis destruction, and even abnormal cell apoptosis [22]. Furthermore, the moment the MPT hole opens, cytochrome c can leak into the cytoplasm, triggering a series of events such as caspase-9 activation that eventually leads to mitochondria-driven apoptosis [23]. Sch B reduces the production of lipid peroxides, which may be one of its molecular mechanisms to protect mitochondrial integrity [12, 20].

3. Schisandrin B and Cancer

Cancer is a pathological condition that has been known since immemorial times by early Egyptians. Despite this ancient lineage (about 3000 B.C.), two modern patterns favor cancers’ incidence, and types encountered longevity and lifestyle. For the etymology of cancer, it was derived from the Greek word karkinos first coined by Hippocrates (460-370 B.C.) while describing the pathology in its structural aspect as a rounded mass surrounded by radial ramifications like a moving, clasping crab. This analogy was an attempt with the breast tumor. He classified cancer based on their size, anatomic sites, and whether it was superficial or deeply embedded at its site [24–26]. Cancer is used as an inclusive name, referring to more than a hundred disease conditions [27]. The pathological conditions are characterized by uncontrolled cell growth beyond boundaries that could start at any anatomical site, then eventually spreading (metastasize) towards the nearby and farthest tissue(s)/organ(s). Like many other epidemic chronic noncommunicable diseases, cancers’ incidence is believed to be a consequence of rapid urbanization, environmental pollution, and changes in lifestyles [28, 29].

Chemotherapies remain one of the most used methods for cancer treatment. These drugs inhibited cancer cell growth, therefore stopping the proliferation of cancer [30, 31]. The cytotoxicity of Sch B was reported against a wide variety of human cancer cell lines (Table 1) with low concentration. The cancer cell inhibition by Sch B was demonstrated to be through several biological pathways, among them cell cycle arrest, apoptosis, ROS production, and autophagy.

3.1. Sch B Induces Cell Cycle

The cell is the anatomical and physiological unit of life. From that place, cell fulfills all the characteristics of living things, namely, functional organization, metabolism, homeostasis, growth and development, reproduction, passing on genetic information, responding to environmental changes, and ability to adapt through evolution. Cell cycle regulation plays a crucial role in cell death. Every phase of the cell cycle is regulated by the interaction of cyclin and their relevant cyclin-dependent kinases (CDKs), which guaranteed one step to another [32, 33].

Four stages, including G1, S, G2, and M, are included in the typical cell cycle governed by cyclin-dependent kinases (CDKs) as well as their cyclin partners. Furthermore, the commitment of distribution appears in the G1 stage, which is governed by cyclin D/CDK4/6 as well as cyclin-E/CDK2 at the alleged G1/S changing. In the S stage, DNA is next repeated. Moreover, a second gap stage, namely, the G2 phase, follows this S stage. At the end of G2 stage, entry was governed by cyclin-B/CDK1 into M stage (karyokinesis) at which the cell splits. Under the specific circumstance, they can go into the cell cycle and start splitting again (Figure 1) [34, 35].

Cyclin/cyclin-dependent kinase (CDK) compounds, essential regulators of RNA copying as well as cell cycle advancement, are of great importance. To guarantee suitable progress through every stage, a suite of checkpoints arranged carefully, which regulate diverse cellular kinases needed for unique cell circle events, has been developed by cells. Notably, as for the mitotic entry as well as chromosome segregation, which guarantee the right forming of daughter cells, some cell circle protein kinases which contain members of Polo-like kinases, as well as the Aurora family, are of great significance [36, 37]. Genetic, as well as epigenetic, mechanisms often linked with the proliferation of the tumor cell and the expression of cell cycle managing proteins are generally influenced by these mechanisms, which lead to inadequate checkpoint governance and cause abnormal responses to cellular harm. Both hyperplasic edges and an additional susceptibility to the accumulation of extra genetic changing contributing to the tumor advancement, as well as the gaining of more invasive phenotypes, are caused by these alterations [38, 39]. Researchers have paid particular attention to identifying anticancer medicines directed against crucial cell cycle regulators in the last years. In particular, CDK or cell cycle protein kinase retardants are solved by some preclinical as well as clinical experiments [40, 41].

Sch B was reported to induce inhibition of human lung cancer, cholangiocarcinoma, gallbladder cancer, and gastric cancer cells through which are mediated by inhibition of cyclin D1, as well as CDK4, and CDK6 promoting activation of p21 and p53. Additionally, Sch B was reported to induce lung cancer cell cycle arrest at G2/M phase mainly through the phosphorylation of the checkpoint of the histone H3 at Ser10, which are the monitors of mitosis (chk1). This report also reported that Sch B, by inhibited ATR protein kinase activity, is involved in the G1/S and S phase checkpoint regulation through inhibition of p53 and cdk1 [42]. Previously, we have found that Sch B induces prostate cancer cell (LNCaP) arrest at S phase by inhibition of cyclin E/CDK2, which is associated with an increase of p53 and p21 [43]. Taken together, these data suggest that Sch B might induce cell cycle arrest in all the phases of the cell cycle in the cancer cell and therefore might be used as an efficient drug in the targets of cell cycle arrest to inhibit cancer cell proliferation.

3.2. Sch B Induces Cell Apoptosis

Apoptosis is the procedure of programmed cell death (PCD), which might appear in multicellular organisms. Biochemical incidents cause typical cell changes (morphology) as well as death. Chromatin condensation, cell shrinkage, chromosomal DNA fragmentation, and nuclear fragmentation are contained in these variations. Researchers reported that the cell is attracted to commit suicide positively in an advancing and homeostatic circumstance; the incentive of suicide might be offered by the lack of some survival factors; specific change in the morphology occurs in there as well as these suicide paths’ biological chemistry; the pathway of “apoptosis” is addressed by someone; and the biochemistry about these suicide paths is followed by a more universal path to delete. However, both of these are generally motivated in a genetic and composite way. There is specific proof that can ensure “apoptosis” symptoms like endonuclease activation. It can be illogically attracted without entering a genetic cascade. Nevertheless, it is necessary to mediate the probably correct apoptosis as well as programmed cell death genetically. In the cancer cell line, apoptosis might occur through a diver’s molecular mechanisms [44, 45].

The induction of apoptosis in a cancer cell by Sch B was firstly reported by Wu et al. [46] in human hepatoma SMMC-7721 cells. This was mediated through intrinsic mitochondrial pathways via Hsp70 and caspases-3, 7, and 9, since plentiful studies reported the cytotoxicity-mediated apoptosis in diver’s cancer notably through extrinsic pathways. Akt pathway regulates many genes and is implied in cell physiopathology that might contribute to the formation of chemoresistance sensitivity or resistances as well as the formation of solid tumors. Regarding its importance, several studies are nowadays focused on this pathway for further cancer therapy. Sch B was reported to induce cytotoxicity of melanoma, prostate, and glioma cancer cells through inhibition of Akt.

Moreover, it was reported that the Akt activation might be causing phosphorylation of specific proteins that cause cell survival, such as NF-κB, which triggers survival caused by phosphorylation of IκB. The studies of Xiang et al. [47] proved that Sch B induces apoptosis in the gallbladder cell through an apoptosis intrinsic pathway via overexpression of Bax and inhibition of Bcl-2 as well as NF-κB with cleavage of PARP, and caspase3/9.

4. Docking System Test

In order to evaluate the efficiency of Sch B compared to Sch A and C, we have performed autodock calculation and then compared the binding affinity as well as binding energies. As observed in Figure 2 and Table 2, Sch B has better binding sites for all cell cycle phases. Indeed, Sch B is able to dock to all cyclin D, E, and A and CDK2 and 4, which are the primary regulator of S, G2, and G1 phases; besides, the binding energy is higher for all cyclin and cyclin-dependent kinase compared to Sch A and C.

Furthermore, it is well known that p53 acts as a tumor suppressor. P53 plays a crucial role in cell growth arrest or apoptosis depending on the cell type or physiological circumstances. Likewise, p53 also positively regulates the protein expression of Bax while negatively regulating Bcl-2 protein expression. Moreover, a recent study reported p53-null mice to have higher levels of Bax while expressing lower expression of Bcl-2 in many tissues. As observed in Figure 3 and Table 2, Sch B has a better binding affinity to Bcl-2, Bax, p53, and caspase-3 (apoptosomes); furthermore, compared to Sch A and C, it is clear that the binding energy of Sch B to this protein is higher compared to Sch A and C. These data suggest that Sch B could be a better target as chemotherapeutic drugs compared to Sch A and C.

The matrix metalloprotease (MMP) family is a kind of endopeptidase which plays an essential role in the invasion and metastasis of tumor cells. MMPs can promote tumor cells to secrete VEGF, which is secreted by tumor cells promoting the secretion of MMPs by vascular endothelial cells. Among MMPs, MMP-2 and MMP-9 belong to the gelatinases in matrix metalloproteinases, which are closely related to the invasion and metastasis of gastric cancer cells. Furthermore, it was reported that MMP-9 and VEGF could play a crucial role in tumor angiogenesis. Moreover, it was further confirmed that MMP-9, like VEGF, may be associated with the occurrence and development of malignancy and maybe an alternative therapeutic target. As observed in Figure 3(b) and Table 2, Sch B has a better affinity with MMP2/9 as well as VEGF, suggesting that Sch B could be a better target in the treatment of gastric cancer compared to Sch A and C.

STAT3 belongs to the family of signal transduction and transcriptional activation. STAT3 plays dual roles in signal transduction and transcriptional activation. The motivated STATs homo- or heterodimerize through mutual SH2 field phosphor-tyrosine roads that are released from the receptor and come into the nucleus, where the transcription of several genetic factors in both rising, as well as adult tissues, is controlled by them. For example, the promoters of Akt, cyclin E, VEGF, Fas, matrix metalloproteinase 2 (MMP2), c-Myc, Mcl-1, HGF, Bcl-xL, and survivin might be bounded to STAT3 in a direct way. As shown in Figure 4 and Table 2, Sch B has a better affinity with STAT3 and Akt compared to Sch A and C. Taken together, Sch B is a better target as chemotherapy drugs for several cancer cells compared to Sch A and C.

5. Schisandrin B and Neuroprotection

Neurodegenerative disease (ND) is characterized by the loss of neurons caused by several burdens among Alzheimer’s and Parkinson’s diseases and cerebrovascular impairment. Although those diseases have a similar symptom, their mechanism differs. Scientists reported that ND is mainly associated with microglia inflammation, and it is the accumulation of those microglia which are responsible for the induction of neurodegenerence through the release of proinflammatory factors such as tumor necrosis factor (TNF), interleukin (IL-6/1β), and nitric oxide (NO) [58, 59]. Those are mainly responsible for neurodegenerence via apoptosis depending on the neuroinflammatory process. Therefore, target novel drugs that might inhibit neuroinflammation and prevent neuron death through apoptosis become preferential targets by researchers to palliative neurodegenerence diseases. S. chinensis has been used since ancestral time in China as a supertonic for brain disorders and has been proven to reverse ischemia as well as improve cognition. Recent studies revealed that Sch B is the main active compound in the use of S. chinensis for neuroprotection. In fact, Sch B was shown to inhibit the protein expression of IL-1β and TNF-α with phosphorylation of MMP-2/9 in the ischemic hemispheres and, therefore, protect rat cerebrum against inflammation as well as metalloproteinase degradation [60]. On the other hand, Sch B was also shown to avoid microglial-mediated inflammatory through inhibited proinflammatory cytokine such as TNF-α, IL-6, PGE2, and NO. The anti-inflammatory activity of Sch B was also related to its ability to interact between Toll-like receptor and their adapter proteins (MyD88, IRAK-1, and TRAF-6), which consequently induce the suppression of IKK transcription factor through NF-κB pathways [61]. Besides, Sch B was shown to reduce oxidative stress by inducing inhibition of MDA and increase SOD expression and therefore prevent hind limb I/R muscle injury [62].

Moreover, recently, several reports have proven that Nrf2 signaling pathways play a role in the antioxidative response element gene by reducing oxidative stress in several diseases, among them cancer, Alzheimer’s and Parkinson’s diseases, and ischemia. Owning its antioxidant properties, Sch B was reported to protect neurodegenerence through inhibition of ROS and malondialdehyde while increasing glutathione and dismutase levels through Nrf2 pathways [63]. Moreover, in Parkinson’s disease, Sch B could decrease cell survival by upregulating the miR34a expression and inhibiting Nrf2 pathways [64]. Finally, in Alzheimer’s disease, Sch B was reported to reduce GSK-3β, a key enzyme necessary for the hyperphosphorylation of tan protein, therefore contributing to the protection of neurons from Alzheimer’s diseases [65]. Table 3 below resumes the recent application of Sch B as neuroprotection.

6. Schisandrin B and Myocardial Ischemia

Worldwide, cardiovascular diseases (CVD) remain one of the most leading causes of mortality. Among CVD, myocardial infarction is the main reason for morbidity in developing countries. Till now, the most efficient cure of myocardial infarction consisted of reperfusion therapy; however, reperfusion could induce inflammatory response or oxidative stress, consequently inducing cellular death. This phenomenon was reported as ischemia/reperfusion (I/R) injury. Regarding this, researchers’ hypothesis identification of novel pharmaceutical drugs that might exert as well as reduce anti-inflammation could prevent the I/R injury in myocardial injury [66–68].

Some mechanism has been reported to prove the efficiency of Sch B in the treatment of myocardial ischemia. Earliest, heat shock treatment could increase myocardial Hsp25 and Hsp70 expressions that could protect against I-R injury under the present experimental conditions. Sch B was reported to prevent I/R enhancing the expression of Hsp25 and Hsp70 [69, 70]. Recently, Sch B was said to reduce myocardial injury through inhibition of oxidative stress and induction of Akt phosphorylation and prevent apoptosis by decreasing the cleavage of caspase-3 [66, 71]. Besides, the apoptosis inhibition of Sch B was associated with its ability to downregulate some inflammatory cytokine through eNOS signaling pathways [72]. Moreover, the inhibition of ROS-mediated cardioprotective activity of Sch B was particularly associated with the ability of Sch B to increase mitochondrial glutathione, which consequently enhances myocardial ATP and therefore protects I/R injury [73, 74].

To sum up, the molecular mechanism of cancer cell regulation and cardioprotection by Sch B was resumed in Figure 5.

7. Conclusion and Further Perspective

In this review, we have emphasized various pharmacological activities of Sch B. Sch B is a natural nonenzymatic antioxidant with low toxicity and low cost and has a broad application prospect oxidation inhibitor; therefore, it could be used in the cure of many diseases. The antitumor activities of Sch B were mainly associated with the induction of cell cycle arrest at different stages and apoptosis mediated through several signaling pathways. Autodock calculation simulation proved that Sch B is a more efficient drug in the regulation of cell cycle and apoptosis compared to Sch A and Sch C.

Although several molecular and classic pathways have been recognized as possible targets of Sch B in the cancer cell line, the long-term toxicities of Sch B must be evaluated in detail in various animal models to inaugurate its safety profile. Pharmacodynamics biomarkers predictive of Sch B tissue exposure as well as probable response are needed. Moreover, no related research on the clinical application of Sch B has been reported yet. Therefore, preclinical and clinical trials are still required to elucidate the full spectrum of anticancer effects of Sch B, either alone or in synergistic combination with existing therapies.

Conflicts of Interest

The authors have declared that no competing interests exist.

Authors’ Contributions

M.IN., S.Z., and C.C. contributed to the conceptualization and collected the data. M.IN., S.Z., C.C., and M.Z. prepared the original draft. M.IN., M.Z., H.H., and P.Z. contributed in reviewing and editing. H.H. and P.Z. helped in funding acquisition. M.IN., S.Z., and C.C. contributed equally to this work.

Acknowledgments

This research was funded by the National Key Research and Development Program of China (2018YFA0108700 and 2017YFA0105602), the NSFC Projects of International Cooperation and Exchanges (81720108004), the National Natural Science Foundation of China (81570279 and 81974019), The Research Team Project of Natural Science Foundation of Guangdong Province of China (2017A030312007), The key program of guangzhou science research plan (805212639211), and The Special Project of Dengfeng Program of Guangdong Provincial People’s Hospital (DFJH201812 and KJ012019119).

References

D. Arauna, M. Furrianca, Y. Espinosa-Parrilla, E. Fuentes, M. Alarcón, and I. Palomo, “Natural bioactive compounds as protectors of mitochondrial dysfunction in cardiovascular diseases and aging,” Molecules, vol. 24, no. 23, p. 4259, 2019.
View at: Publisher Site | Google Scholar
S. Subramaniam, K. R. Selvaduray, and A. K. Radhakrishnan, “Bioactive compounds: natural defense against cancer?” Biomolecules, vol. 9, no. 12, p. 758, 2019.
View at: Publisher Site | Google Scholar
S. Li and B. Zhang, “Traditional Chinese medicine network pharmacology: theory, methodology and application,” Chinese Journal of Natural Medicines, vol. 11, no. 2, pp. 110–120, 2013.
View at: Publisher Site | Google Scholar
S. H. Liu, W. C. Chuang, W. Lam, Z. Jiang, and Y. C. Cheng, “Safety surveillance of traditional Chinese medicine: current and future,” Drug Safety, vol. 38, no. 2, pp. 117–128, 2015.
View at: Publisher Site | Google Scholar
P. Hao, F. Jiang, J. Cheng, L. Ma, Y. Zhang, and Y. Zhao, “Traditional Chinese medicine for cardiovascular disease: evidence and potential mechanisms,” Journal of the American College of Cardiology, vol. 69, no. 24, pp. 2952–2966, 2017.
View at: Publisher Site | Google Scholar
E. J. Jeong, H. K. Lee, K. Y. Lee et al., “The effects of lignan-riched extract of Shisandra chinensis on amyloid-β-induced cognitive impairment and neurotoxicity in the cortex and hippocampus of mouse,” Journal of Ethnopharmacology, vol. 146, no. 1, pp. 347–354, 2013.
View at: Publisher Site | Google Scholar
B. Yu, D. Sheng, and Q. Tan, “Determination of Schisandrin A and Schisandrin B in traditional Chinese medicine preparation huganpian tablet by RP-HPLC,” Chemical & Pharmaceutical Bulletin, vol. 67, no. 7, pp. 713–716, 2019.
View at: Publisher Site | Google Scholar
J. W. Wang, F. Y. Liang, X. S. Ouyang, P. B. Li, Z. Pei, and W. W. Su, “Evaluation of neuroactive effects of ethanol extract of Schisandra chinensis, Schisandrin, and Schisandrin B and determination of underlying mechanisms by zebrafish behavioral profiling,” Chinese Journal of Natural Medicines, vol. 16, no. 12, pp. 916–925, 2018.
View at: Publisher Site | Google Scholar
P. K. Leong and K. M. Ko, “Schisandrin B: a double-edged sword in nonalcoholic fatty liver disease,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 6171658, 13 pages, 2016.
View at: Publisher Site | Google Scholar
P. Y. Lam and K. M. Ko, “Schisandrin B as a hormetic agent for preventing age-related neurodegenerative diseases,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 250825, 9 pages, 2012.
View at: Publisher Site | Google Scholar
E. P. Jiang, H. Li, C. R. Yu et al., “Schisandrin B protects PC12 cells against oxidative stress of neurodegenerative diseases,” NeuroReport, vol. 26, no. 6, pp. 360–366, 2015.
View at: Publisher Site | Google Scholar
P. K. Leong, N. Chen, and K. M. Ko, “Mitochondrial decay in ageing: 'Qi-invigorating' schisandrin B as a hormetic agent for mitigating age-related diseases,” Clinical and Experimental Pharmacology & Physiology, vol. 39, no. 3, pp. 256–264, 2012.
View at: Publisher Site | Google Scholar
S. R. Kim, M. K. Lee, K. A. Koo et al., “Dibenzocyclooctadiene lignans from Schisandra chinensis protect primary cultures of rat cortical cells from glutamate-induced toxicity,” Journal of Neuroscience Research, vol. 76, no. 3, pp. 397–405, 2004.
View at: Publisher Site | Google Scholar
S. P. Ip and K. M. Ko, “The crucial antioxidant action of schisandrin B in protecting against carbon tetrachloride hepatotoxicity in mice: a comparative study with butylated hydroxytoluene,” Biochemical Pharmacology, vol. 52, no. 11, pp. 1687–1693, 1996.
View at: Publisher Site | Google Scholar
P. Y. Chiu, H. Y. Leung, and K. M. Ko, “Schisandrin B enhances renal mitochondrial antioxidant status, functional and structural integrity, and protects against gentamicin-induced nephrotoxicity in rats,” Biological & Pharmaceutical Bulletin, vol. 31, no. 4, pp. 602–605, 2008.
View at: Publisher Site | Google Scholar
Y. Deng, Z. Xu, B. Xu, W. Liu, S. Feng, and T. Yang, “Antioxidative effects of schidandrin B and green tea polyphenols against mercuric chloride-induced hepatotoxicity in rats,” Journal of Environmental Pathology, Toxicology and Oncology, vol. 33, no. 4, pp. 349–361, 2014.
View at: Publisher Site | Google Scholar
W. Liu, Z. Xu, H. Yang, Y. Deng, B. Xu, and Y. Wei, “The protective effects of tea polyphenols and schisandrin B on nephrotoxicity of mercury,” Biological Trace Element Research, vol. 143, no. 3, pp. 1651–1665, 2011.
View at: Publisher Site | Google Scholar
V. V. Giridharan, R. A. Thandavarayan, S. Arumugam et al., “Schisandrin B ameliorates ICV-infused amyloid β induced oxidative stress and neuronal dysfunction through inhibiting RAGE/NF-κB/MAPK and up-regulating HSP/Beclin expression,” PLoS One, vol. 10, no. 11, article e0142483, 2015.
View at: Publisher Site | Google Scholar
H. Ichikawa, L. Wang, and T. Konishi, “Prevention of cerebral oxidative injury by post-ischemic intravenous administration of Shengmai San,” The American Journal of Chinese Medicine, vol. 34, no. 4, pp. 591–600, 2006.
View at: Publisher Site | Google Scholar
N. Chen, P. Y. Chiu, and K. M. Ko, “Schisandrin B enhances cerebral mitochondrial antioxidant status and structural integrity, and protects against cerebral ischemia/reperfusion injury in rats,” Biological & Pharmaceutical Bulletin, vol. 31, no. 7, pp. 1387–1391, 2008.
View at: Publisher Site | Google Scholar
P. Y. Chiu, D. H. F. Mak, M. K. T. Poon, and K. M. Ko, “Role of cytochrome P-450 in schisandrin B-induced antioxidant and heat shock responses in mouse liver,” Life Sciences, vol. 77, no. 23, pp. 2887–2895, 2005.
View at: Publisher Site | Google Scholar
J. S. Kim, L. He, and J. J. Lemasters, “Mitochondrial permeability transition: a common pathway to necrosis and apoptosis,” Biochemical and Biophysical Research Communications, vol. 304, no. 3, pp. 463–470, 2003.
View at: Publisher Site | Google Scholar
R. Jemmerson, J. M. Dubinsky, and N. Brustovetsky, “Cytochrome c release from CNS mitochondria and potential for clinical intervention in apoptosis-mediated CNS diseases,” Antioxidants & Redox Signaling, vol. 7, no. 9-10, pp. 1158–1172, 2005.
View at: Publisher Site | Google Scholar
S. I. Hajdu, “A note from history: landmarks in history of cancer, part 1,” Cancer, vol. 117, no. 5, pp. 1097–1102, 2010.
View at: Publisher Site | Google Scholar
R. B. Robey, “Changing the terminology of cancer,” JAMA, vol. 311, no. 2, pp. 202-203, 2014.
View at: Publisher Site | Google Scholar
S. H. Yan, “An early history of human breast cancer: West meets East,” Chinese Journal of Cancer, vol. 32, no. 9, pp. 475–477, 2013.
View at: Publisher Site | Google Scholar
C. Greenman, P. Stephens, R. Smith et al., “Patterns of somatic mutation in human cancer genomes,” Nature, vol. 446, no. 7132, pp. 153–158, 2007.
View at: Publisher Site | Google Scholar
W. Chen, R. Zheng, S. Zhang et al., “Cancer incidence and mortality in China in 2013: an analysis based on urbanization level,” Chinese Journal of Cancer Research, vol. 29, no. 1, pp. 1–10, 2017.
View at: Publisher Site | Google Scholar
M. Pedersen, Z. J. Andersen, M. Stafoggia et al., “Ambient air pollution and primary liver cancer incidence in four European cohorts within the ESCAPE project,” Environmental Research, vol. 154, pp. 226–233, 2017.
View at: Publisher Site | Google Scholar
Z. F. Lim and P. C. Ma, “Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy,” Journal of Hematology & Oncology, vol. 12, no. 1, p. 134, 2019.
View at: Publisher Site | Google Scholar
O. Maertens, M. E. McCurrach, B. S. Braun et al., “A collaborative model for accelerating the discovery and translation of cancer therapies,” Cancer Research, vol. 77, no. 21, pp. 5706–5711, 2017.
View at: Publisher Site | Google Scholar
J. T. P. Yeeles, T. D. Deegan, A. Janska, A. Early, and J. F. X. Diffley, “Regulated eukaryotic DNA replication origin firing with purified proteins,” Nature, vol. 519, no. 7544, pp. 431–435, 2015.
View at: Publisher Site | Google Scholar
L. N. Kent and G. Leone, “The broken cycle: E2F dysfunction in cancer,” Nature Reviews Cancer, vol. 19, no. 6, pp. 326–338, 2019.
View at: Publisher Site | Google Scholar
R. Suryadinata, M. Sadowski, and B. Sarcevic, “Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (CDK) substrates,” Bioscience Reports, vol. 30, no. 4, pp. 243–255, 2010.
View at: Publisher Site | Google Scholar
U. Asghar, A. K. Witkiewicz, N. C. Turner, and E. S. Knudsen, “The history and future of targeting cyclin-dependent kinases in cancer therapy,” Nature Reviews Drug Discovery, vol. 14, no. 2, pp. 130–146, 2015.
View at: Publisher Site | Google Scholar
T. Ishidate, A. Elewa, S. Kim, C. C. Mello, and M. Shirayama, “Divide and differentiate: CDK/Cyclins and the art of development,” Cell Cycle, vol. 13, no. 9, pp. 1384–1391, 2014.
View at: Publisher Site | Google Scholar
P. Chymkowitch and J. M. Enserink, “The cell cycle rallies the transcription cycle: Cdc 28/Cdk 1 is a cell cycle-regulated transcriptional CDK,” Transcription, vol. 4, no. 1, pp. 3–6, 2013.
View at: Publisher Site | Google Scholar
L. Santo, K. T. Siu, and N. Raje, “Targeting cyclin-dependent kinases and cell cycle progression in human cancers,” Seminars in Oncology, vol. 42, no. 6, pp. 788–800, 2015.
View at: Publisher Site | Google Scholar
L. He, N. Lu, Q. Dai et al., “Wogonin induced G1 cell cycle arrest by regulating Wnt/β-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells,” Toxicology, vol. 312, pp. 36–47, 2013.
View at: Publisher Site | Google Scholar
J. Ettl, “Palbociclib: first CDK4/6 inhibitor in clinical practice for the treatment of advanced HR-positive breast cancer,” Breast Care, vol. 11, no. 3, pp. 174–176, 2016.
View at: Publisher Site | Google Scholar
M. Zajac, I. Muszalska, and A. Jelinska, “New molecular targets of anticancer therapy-current status and perspectives,” Current Medicinal Chemistry, vol. 23, no. 37, pp. 4176–4220, 2016.
View at: Publisher Site | Google Scholar
H. Nishida, N. Tatewaki, Y. Nakajima et al., “Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response,” Nucleic Acids Research, vol. 37, no. 17, pp. 5678–5689, 2009.
View at: Publisher Site | Google Scholar
M. I. Nasser, T. Han, S. Adlat, Y. Tian, and N. Jiang, “Inhibitory effects of Schisandrin B on human prostate cancer cells,” Oncology Reports, vol. 41, no. 1, pp. 677–685, 2018.
View at: Publisher Site | Google Scholar
J. G. Nirmala and M. Lopus, “Cell death mechanisms in eukaryotes,” Cell Biology and Toxicology, 2019.
View at: Publisher Site | Google Scholar
S. Kaczanowski, “Apoptosis: its origin, history, maintenance and the medical implications for cancer and aging,” Physical Biology, vol. 13, no. 3, article 031001, 2016.
View at: Publisher Site | Google Scholar
Y. F. Wu, M. F. Cao, Y. P. Gao et al., “Down-modulation of heat shock protein 70 and up-modulation of Caspase-3 during schisandrin B-induced apoptosis in human hepatoma SMMC-7721 cells,” World Journal of Gastroenterology, vol. 10, no. 20, pp. 2944–2948, 2004.
View at: Publisher Site | Google Scholar
S. S. Xiang, X. A. Wang, H. F. Li et al., “Schisandrin B induces apoptosis and cell cycle arrest of gallbladder cancer cells,” Molecules, vol. 19, no. 9, pp. 13235–13250, 2016.
View at: Publisher Site | Google Scholar
J. Li, Y. Lu, D. Wang et al., “Schisandrin B prevents ulcerative colitis and colitis-associated-cancer by activating focal adhesion kinase and influence on gut microbiota in an in vivo and in vitro model,” European Journal of Pharmacology, vol. 854, pp. 9–21, 2019.
View at: Publisher Site | Google Scholar
X. Dai, C. Yin, G. Guo et al., “Schisandrin B exhibits potent anticancer activity in triple negative breast cancer by inhibiting STAT3,” Toxicology and Applied Pharmacology, vol. 358, pp. 110–119, 2018.
View at: Publisher Site | Google Scholar
S. Wang, A. Wang, M. Shao, L. Lin, P. Li, and Y. Wang, “Schisandrin B reverses doxorubicin resistance through inhibiting P-glycoprotein and promoting proteasome-mediated degradation of survivin,” Scientific Reports, vol. 7, no. 1, p. 8419, 2017.
View at: Publisher Site | Google Scholar
Z. Liu, B. Zhang, K. Liu, Z. Ding, and X. Hu, “Schisandrin B attenuates cancer invasion and metastasis via inhibiting epithelial-mesenchymal transition,” PLoS One, vol. 7, no. 7, article e40480, 2012.
View at: Publisher Site | Google Scholar
X. J. Lv, L. J. Zhao, Y. Q. Hao et al., “Schisandrin B inhibits the proliferation of human lung adenocarcinoma A549 cells by inducing cycle arrest and apoptosis,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 5, pp. 6926–6936, 2015.
View at: Google Scholar
X. R. He, S. Y. Han, X. H. Li et al., “Chinese medicine Bu-Fei decoction attenuates epithelial-mesenchymal transition of non-small cell lung cancer via inhibition of transforming growth factor β1 signaling pathway in vitro and in vivo,” Journal of Ethnopharmacology, vol. 204, pp. 45–57, 2017.
View at: Publisher Site | Google Scholar
Y. Jiang, Q. Zhang, J. Bao et al., “Schisandrin B inhibits the proliferation and invasion of glioma cells by regulating the HOTAIR-micoRNA-125a-mTOR pathway,” NeuroReport, vol. 28, no. 2, pp. 93–100, 2017.
View at: Publisher Site | Google Scholar
Z. Zhang, Y. Wang, J. Chen et al., “Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity,” Cancer Chemotherapy and Pharmacology, vol. 78, no. 6, pp. 1289–1296, 2016.
View at: Publisher Site | Google Scholar
Q. Li, X. H. Lu, C. D. Wang et al., “Antiproliferative and apoptosis-inducing activity of schisandrin B against human glioma cells,” Cancer Cell International, vol. 15, no. 1, p. 12, 2015.
View at: Publisher Site | Google Scholar
X. Yang, S. Wang, Y. Mu, and Y. Zheng, “Schisandrin B inhibits cell proliferation and induces apoptosis in human cholangiocarcinoma cells,” Oncology Reports, vol. 36, no. 4, pp. 1799–1806, 2016.
View at: Publisher Site | Google Scholar
V. Calabrese, A. Santoro, D. Monti et al., “Aging and Parkinson's disease: inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis,” Free Radical Biology & Medicine, vol. 115, pp. 80–91, 2018.
View at: Publisher Site | Google Scholar
E. C. Stamouli and A. M. Politis, “Pro-inflammatory cytokines in Alzheimer's disease,” Psychiatriki, vol. 27, no. 4, pp. 264–275, 2016.
View at: Publisher Site | Google Scholar
T. H. Lee, C. H. Jung, and D. H. Lee, “Neuroprotective effects of Schisandrin B against transient focal cerebral ischemia in Sprague–Dawley rats,” Food and Chemical Toxicology, vol. 50, no. 12, pp. 4239–4245, 2012.
View at: Publisher Site | Google Scholar
K. W. Zeng, T. Zhang, H. Fu, G. X. Liu, and X. M. Wang, “Schisandrin B exerts anti-neuroinflammatory activity by inhibiting the Toll- like receptor 4-dependent MyD88/IKK/NF-κB signaling pathway in lipopolysaccharide-induced microglia,” European Journal of Pharmacology, vol. 692, no. 1-3, pp. 29–37, 2012.
View at: Publisher Site | Google Scholar
N. Zhu, C. Cai, A. Zhou, X. Zhao, Y. Xiang, and C. Zeng, “Schisandrin B prevents hind limb from ischemia-reperfusion-induced oxidative stress and inflammation via MAPK/NF-κB pathways in rats,” BioMed Research International, vol. 2017, Article ID 4237973, 8 pages, 2017.
View at: Publisher Site | Google Scholar
Y. Wu, Z. C. Li, L. Q. Yao, M. Li, and M. Tang, “Schisandrin B alleviates acute oxidative stress via modulation of the Nrf2/Keap1-mediated antioxidant pathway,” Applied Physiology, Nutrition, and Metabolism, vol. 44, no. 1, pp. 1–6, 2019.
View at: Publisher Site | Google Scholar
Q. Ba, C. Cui, L. Wen, S. Feng, J. Zhou, and K. Yang, “Schisandrin B shows neuroprotective effect in 6-OHDA-induced Parkinson's disease via inhibiting the negative modulation of miR-34a on Nrf2 pathway,” Biomedicine & Pharmacotherapy, vol. 75, pp. 165–172, 2015.
View at: Publisher Site | Google Scholar
X. L. Hu, C. Guo, J. Q. Hou et al., “Stereoisomers of Schisandrin B are potent ATP competitive GSK-3β inhibitors with neuroprotective effects against Alzheimer's disease: stereochemistry and biological activity,” ACS Chemical Neuroscience, vol. 10, no. 2, pp. 996–1007, 2019.
View at: Publisher Site | Google Scholar
X. Zhao, Y. Xiang, C. Cai, A. Zhou, N. Zhu, and C. Zeng, “Schisandrin B protects against myocardial ischemia/reperfusion injury via the PI3K/Akt pathway in rats,” Molecular Medicine Reports, vol. 17, no. 1, pp. 556–561, 2017.
View at: Publisher Site | Google Scholar
A. Caricati-Neto, P. R. Errante, and F. S. Menezes-Rodrigues, “Recent advances in pharmacological and non-pharmacological strategies of cardioprotection,” International Journal of Molecular Sciences, vol. 20, no. 16, article 4002, 2019.
View at: Publisher Site | Google Scholar
M. Tibaut, D. Mekis, and D. Petrovic, “Pathophysiology of myocardial infarction and acute management strategies,” Cardiovascular & Hematological Agents in Medicinal Chemistry, vol. 14, no. 3, pp. 150–159, 2016.
View at: Publisher Site | Google Scholar
K. M. Ko and P. Y. Chiu, “Structural determinants of schisandrin B which enhance mitochondrial functional ability and glutathione status as well as heat shock protein expression in rat hearts and H9c2 cells,” Molecular and Cellular Biochemistry, vol. 276, no. 1-2, pp. 227–234, 2004.
View at: Publisher Site | Google Scholar
P. Y. Chiu and K. M. Ko, “Schisandrin B protects myocardial ischemia-reperfusion injury partly by inducing Hsp25 and Hsp70 expression in rats,” Molecular and Cellular Biochemistry, vol. 266, no. 1/2, pp. 139–144, 2004.
View at: Publisher Site | Google Scholar
W. Zhang, Z. Sun, and F. Meng, “Schisandrin B ameliorates myocardial ischemia/reperfusion injury through attenuation of endoplasmic reticulum stress-induced apoptosis,” Inflammation, vol. 40, no. 6, pp. 1903–1911, 2017.
View at: Publisher Site | Google Scholar
P. Chen, S. Pang, N. Yang et al., “Beneficial effects of schisandrin B on the cardiac function in mice model of myocardial infarction,” PLoS One, vol. 8, no. 11, article e79418, 2013.
View at: Publisher Site | Google Scholar
N. Chen and M. Ko, “Schisandrin B-induced glutathione antioxidant response and cardioprotection are mediated by reactive oxidant species production in rat hearts,” Biological & Pharmaceutical Bulletin, vol. 33, no. 5, pp. 825–829, 2010.
View at: Publisher Site | Google Scholar
P. Y. Chiu and K. M. Ko, “Time-dependent enhancement in mitochondrial glutathione status and ATP generation capacity by schisandrin B treatment decreases the susceptibility of rat hearts to ischemia-reperfusion injury,” BioFactors, vol. 19, no. 1-2, pp. 43–51, 2003.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2020 M. I. Nasser et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

3387

Downloads

1435

Citations